As it well known, children can heal their skin much more easily than adults, after an injury. This is because there are molecules exclusively present during childhood and lost in adult life. Our solution intends to recapitulate this pro-regenerative environment, leading to the re-expression of unique fetal and neonatal features, which will promote intervertebral disc regeneration.

A healthy intervertebral disc has very few blood vessels. As the disc ages and degenerates, new blood vessels and nerves can grow into regions that are normally avascular and aneural. This is linked to inflammation and can contribute to chronic low back pain.
Fetalix's biomaterial creates and environment that supports the body's natural repair processes while also helping maintain the disc's normal structure by limiting the growth of unwanted blood vessels. By encouraging tissue regeneration and preserving the disc's natural environment, Fetalix aims to address the underlying causes of degeneration rather than simply relieving symptoms.

Fetalix is designed to be injected directly into the damaged intervertebral disc using a fine needle. The procedure is minimally invasive, meaning it does not require major surgery and is intended to be performed with imaging guidance to ensure the biomaterial is delivered precisely to the affected area.

Fetalix is designed to create an environment that supports cell-mediated repair of damaged tissue. It contains natural biological signals presente in fetal tissues, which encourage cells in the damaged disc to produce the healthy proteins needed to rebuild and maintain the disc.

At this stage, Fetalix is being developed to treat patients with early-to-moderate degenerative disc disease, a common cause of chronic low back pain. This is the condition in which the technology is being tested in preclinical studies.
Looking ahead, we believe the same regenerative approach could also be used to help prevent disc degeneration in people at risk or to treat other cartilage-related conditions, such as osteoarthritis. However, these potential applications will require further research and validation.

Fetalix is made from decellularized fetal bovine tissue, meaning the cells that could trigger an immune response are removed while preserving the natural biological signals that support tissue repair.
Decellularized biomaterials have been widely studied and are commonly used in regenerative medicine because they are designed to minimize the risk of adverse immune reactions. As Fetalix is still in the preclinical stage, its safety will continue to be carefully evaluated through additional preclinical studies and future clinical trials before it can be used in patients.

Current treatments for degenerative disc disease mainly focus on managing pain with medications or, in more advanced cases, treating the condition with surgery. While these approaches can help relieve symptoms, they do not repair the damaged disc or restore its normal function.
Fetalix is different because it is designed to address the underlying cause of disc degeneration. Instead of replacing tissue or simply reducing pain, it creates an environment that helps the body's own cells repair the damaged disc. It is also a minimally invasive, injectable treatment with the potential to slow disease progression and reduce the need for surgery.